摘要
目的探讨环氧化酶-2(COX-2)在人膀胱移行细胞癌(TCC)中的表达及其临床意义。方法采用S-P免疫组化技术分别研究70例膀胱TCC和18例膀胱良性病变组织中COX-2)的表达,并研究其表达水平与患者各临床病理参数之间的关系。结果COX-2的表达主要位于肿瘤细胞的胞浆中,表达阳性率为72.9%,高于其在良性病变组织中的表达水平(P<0.01)。COX-2的表达程度与肿瘤的大小及病理分级相关(P均<0.05),COX-2在不同病理分期之间的表达水平差异有统计学意义(P<0.01),但初发与复发肿瘤之间以及多发与单发肿瘤之间COX-2的表达水平差异均无统计学意义(P均>0.05)。单因素分析,COX-2表达与膀胱癌的复发无关(P>0.05)。结论COX-2表达与膀胱TCC的侵袭性密切相关,虽然COX-2并非膀胱移行细胞癌复发的独立预后因素,但可作为肿瘤治疗的一个重要靶点。
Objective To assess the possible relationship between cyclooxygenase-2 （COX-2） immunoreactivity in human bladder transitional cell carcinoma （TCC） and tumor grade, stage, recurrence of disease. Methods SP two-steps immunohistochemistry was applied to detect the expression pattern of COX-2 in 70 bladder TCC tissues and 18 bladder tissues with benign lesions. The possible association of COX-2 with the clinicopathologic parameters was evaluated. Results Most COX-2 imrnunoreactivity was observed in the cytoplasm of tumor cells, positive expression was found in 72.9 % patients with TCC. The expression rate in bladder TCC tissues was significantly higher than that in 18 benign bladder tissues （P〈0. 01） . COX-2 over expression was associated with tumor grade （P=0. 041）, stage （P〈0. 01） and size （by using 4. 0 cm as a cutoff, P〈0.05）. There was no significant difference in the COX-2 expression rate between the primary and recurrent TCC groups or between single and multiple TCC groups. Single factor analysis revealed no association between COX-2 expression and tumor recurrence. Conclusions COX-2 over expression in bladder TCC is associated with tumor invasiveness. While COX-2 expression has limited prognostic value in patients with TCC, it may serve as an important target for therapy.
出处
《福建医药杂志》
CAS
2007年第5期6-8,共3页
Fujian Medical Journal
基金
福建省自然科学基金资助项目(C0110023)
